Pegging the Value of Gene Discovery
About a dozen major alliances have been formed over the past 18 months involving commercial rights to novel genes and gene sequences. The upfront commitment of equity and research dollars continues to be impressive, but the value of each deal more often falls in line with the needs of the individual customers. For gene discovery companies, the next hurdle is how to sustain the value of their technologies as genomic information becomes more broadly available.
You may also be interested in...
Thermo Fisher Scientific has agreed to buy Mesa Biotech for $450m in cash and Hillrom will acquire Bardy Diagnostics for $375m in cash. Both deals will add complementary digital health solutions, which may be a continued trend in 2021.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Medicare now covers transcatheter edge-to-edge repair for both functional and degenerative mitral regurgitation under specific conditions.